| OMEROS CORP. DL -,01 |
| USA |
| Gesundheit |
| US6821431029 / A0NBFF |
| 3O8 (Frankfurt) / OMER (NASDAQ) |
| FRA:3O8, ETR:3O8, 3O8:GR, NASDAQ:OMER |
| - |
| https://www.omeros.com/ |
|
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in are..
>Volltext.. |
| 601.38 Mio. EUR |
| 877.87 Mio. EUR |
| - |
| -110.97 Mio. EUR |
| -104.76 Mio. EUR |
| -1.74 EUR |
| 314.24 Mio. EUR |
| 2.07 Mio. EUR |
| -90.99 Mio. EUR |
| 0.45 |
| - |
| 14.54% |
| - |
| - |
| - |
| - |
| OMEROS |
| 01.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|